can you take cjc 1295 dac with ipamorelin CJC-1295 + cjc 1295 no dac ipamorelin

Pharmacological intervention with rosiglitazone, an ACSL4 inhibitor, led to a 44% reduction in 4-hydroxynonenal (4-HNE) levels and a 42% decrease in A plaque deposition in brain tissues

IPTW-adjusted analyses similarly found no significant differences in 90-day good outcomes (adjusted odds ratio [aOR], 0.82

Rodent studies have used approximately 1 to 10 micrograms per kilogram of body weight, often administered subcutaneously or intraperitoneally

FDA & Medical Community Stance The FDA has not approved any eye drops as a cure for cataracts yet

Barbagallo M, Dominguez LJ, Tagliamonte MR, Resnick LM, Paolisso G

N Engl J Med (2019) 380(21):19972008